SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced a pipeline refocusing, adding a new glioblastoma…

Evaxion A/S · 6-K filed Aug 17, 2026 at 08:05 ET

At the news

NEUTRALIMPACT 4/10

6-K filed Aug 17, 2026 at 08:05 ET

Evaxion announced a pipeline refocusing, adding a new glioblastoma vaccine program (EVX-05) in collaboration with Duke University while discontinuing the EVX-03 program. The company reiterated its cash runway into H2 2027 and stated EVX-05 costs are within existing budgets, but no financial figures or clinical data were provided. This is a preclinical-stage pipeline update with no near-term revenue or catalyst data.

  • New glioblastoma vaccine program EVX-05 announced, off-the-shelf, targeting ERV-derived antigens, in collaboration with Duke University.
  • Evaxion maintains cash runway into the second half of 2027; EVX-05 costs are within existing budgets.
  • EVX-03 program discontinued.
  • No financial figures, clinical data, or guidance were provided in this filing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access